MEDP

MEDP

USD

Medpace Holdings Inc. Common Stock

$301.565-0.055 (-0.018%)

リアルタイム価格

Healthcare
Diagnostics & Research
米国

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$301.620

高値

$301.910

安値

$301.170

出来高

0.31M

企業ファンダメンタルズ

時価総額

8.7B

業種

Diagnostics & Research

United States

取引統計

平均出来高

0.49M

取引所

NMS

通貨

USD

52週レンジ

安値 $250.05現在値 $301.565高値 $459.77

関連ニュース

Analyst Upgrades

Truist Securities Maintains Hold on Medpace Hldgs, Lowers Price Target to $300

Truist Securities analyst Jailendra Singh maintains Medpace Hldgs with a Hold and lowers the price target from $333 to $300.

もっと見る
Truist Securities Maintains Hold on Medpace Hldgs, Lowers Price Target to $300
Analyst Upgrades

Baird Maintains Neutral on Medpace Hldgs, Lowers Price Target to $313

Baird analyst Eric Coldwell maintains Medpace Hldgs with a Neutral and lowers the price target from $340 to $313.

もっと見る
Baird Maintains Neutral on Medpace Hldgs, Lowers Price Target to $313
Analyst Upgrades

William Blair Downgrades Medpace Hldgs to Market Perform

William Blair analyst Max Smock downgrades Medpace Hldgs from Outperform to Market Perform.

もっと見る
William Blair Downgrades Medpace Hldgs to Market Perform
BusinessWire

Medpace Holdings, Inc. Reports First Quarter 2025 Results

Revenue of $558.6 million in the first quarter of 2025 increased 9.3% from revenue of $511.0 million for the comparable prior-year period, representing a backlog conversion rate of 19.2%. Net new business awards were

もっと見る
Medpace Holdings, Inc. Reports First Quarter 2025 Results
Analyst Upgrades

TD Cowen Downgrades Medpace Hldgs to Hold, Lowers Price Target to $328

TD Cowen analyst Charles Rhyee downgrades Medpace Hldgs from Buy to Hold and lowers the price target from $370 to $328.

もっと見る
TD Cowen Downgrades Medpace Hldgs to Hold, Lowers Price Target to $328
Analyst Upgrades

Truist Securities Maintains Hold on Medpace Hldgs, Lowers Price Target to $333

Truist Securities analyst Jailendra Singh maintains Medpace Hldgs with a Hold and lowers the price target from $347 to $333.

Analyst Upgrades

Mizuho Maintains Outperform on Medpace Hldgs, Lowers Price Target to $355

Mizuho analyst Ann Hynes maintains Medpace Hldgs with a Outperform and lowers the price target from $400 to $355.